A potent fully human anti-CTGF antibody prevents skin fibrosis and keloid progression via attenuation of Smad and MAPK/Akt signaling

Background Pathological skin fibrosis, encompassing systemic sclerosis (SSc) and keloids, represents a substantial unmet clinical need due to the narrow therapeutic window of transforming growth factor-β (TGF-β)–targeted interventions. Although connective tissue growth factor (CTGF) serves as a safer key downstream target, fully human anti-CTGF biologics that preserve physiological wound healing remain elusive. Methods We developed 12–005, a fully human monoclonal antibody targeting CTGF, and evaluated its biochemical properties by assessing binding kinetics and cross-species reactivity. In vivo prophylactic efficacy was assessed using a bleomycin-induced SSc murine model, while therapeutic potential was evaluated in a patient-derived human keloid fibroblast (KEL FIB) xenograft model. The underlying molecular mechanisms of action were elucidated utilizing engineered fibroblast and human mesenchymal stem cell (hMSC) in vitro systems. Furthermore, a full-thickness skin excisional wound model was employed to verify that 12–005 administration preserves normal physiological tissue repair. Results 12–005 exhibited sub-nanomolar binding affinity, with an equilibrium dissociation constant ( K D ) of 1.11 × 10 −10 M, alongside robust cross-species reactivity. In the SSc murine model, 12–005 administration significantly attenuated dermal thickness and collagen deposition. In the KEL FIB xenograft model, it markedly suppressed lesion growth and myofibroblast activation. Mechanistically, 12–005 targeted CTGF within the fibrotic microenvironment, thereby attenuating both the canonical Smad2/3-dependent and non-canonical extracellular signal-regulated kinase (ERK)/mitogen-activated protein kinase (MAPK) and Akt signaling cascades. Notably, at therapeutically effective doses, 12–005 neither delayed wound closure nor impaired re-epithelialization, thereby preserving normal physiological healing capacity. Conclusions 12–005 attenuates pathological fibrosis via the dual attenuation of the Smad and MAPK/Akt signaling pathways, positioning it as a promising anti-CTGF antibody candidate for the treatment of fibrotic skin diseases.

Authors

Institutions

Publication Details

Journal
International Immunopharmacology
Published
2026-11-21
DOI
https://doi.org/10.1016/j.intimp.2026.117716
Primary Topic
Systemic Sclerosis and Related Diseases
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

A potent fully human anti-CTGF antibody prevents skin fibrosis and keloid progression via attenuation of Smad and MAPK/Akt signaling

Peizhu Tan, Jiayi Zhao, Na Cai, Yanze Li et al.
International Immunopharmacology
Systemic Sclerosis and Related Diseases
article

A potent fully human anti-CTGF antibody prevents skin fibrosis and keloid progression via attenuation of Smad and MAPK/Akt signaling

Peizhu Tan, Jiayi Zhao, Na Cai, Yanze Li, Xu Gao, Bowei Liu, Hui Huang, Lingyun Zhou, Anqi Cao, Xiuchen Xuan, Haonan Shi, Jiazhen Zhang
article en

Abstract

Background Pathological skin fibrosis, encompassing systemic sclerosis (SSc) and keloids, represents a substantial unmet clinical need due to the narrow therapeutic window of transforming growth factor-β (TGF-β)–targeted interventions. Although connective tissue growth factor (CTGF) serves as a safer key downstream target, fully human anti-CTGF biologics that preserve physiological wound healing remain elusive. Methods We developed 12–005, a fully human monoclonal antibody targeting CTGF, and evaluated its biochemical properties by assessing binding kinetics and cross-species reactivity. In vivo prophylactic efficacy was assessed using a bleomycin-induced SSc murine model, while therapeutic potential was evaluated in a patient-derived human keloid fibroblast (KEL FIB) xenograft model. The underlying molecular mechanisms of action were elucidated utilizing engineered fibroblast and human mesenchymal stem cell (hMSC) in vitro systems. Furthermore, a full-thickness skin excisional wound model was employed to verify that 12–005 administration preserves normal physiological tissue repair. Results 12–005 exhibited sub-nanomolar binding affinity, with an equilibrium dissociation constant ( K D ) of 1.11 × 10 −10 M, alongside robust cross-species reactivity. In the SSc murine model, 12–005 administration significantly attenuated dermal thickness and collagen deposition. In the KEL FIB xenograft model, it markedly suppressed lesion growth and myofibroblast activation. Mechanistically, 12–005 targeted CTGF within the fibrotic microenvironment, thereby attenuating both the canonical Smad2/3-dependent and non-canonical extracellular signal-regulated kinase (ERK)/mitogen-activated protein kinase (MAPK) and Akt signaling cascades. Notably, at therapeutically effective doses, 12–005 neither delayed wound closure nor impaired re-epithelialization, thereby preserving normal physiological healing capacity. Conclusions 12–005 attenuates pathological fibrosis via the dual attenuation of the Smad and MAPK/Akt signaling pathways, positioning it as a promising anti-CTGF antibody candidate for the treatment of fibrotic skin diseases.

International ImmunopharmacologyVol. 191
Harbin Medical University (CN), Education Department of Heilongjiang Province (CN), Heilongjiang University (CN)
Systemic Sclerosis and Related Diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon